NFKB1
Reactivity: Human
WB, IHC, ELISA, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 1:1000. IHC-P: 1:25. IHC-P: 1:25. FC: 1:25
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified monoclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Expiry Date
6 months
Héron, Deloukas, van Loon: "The complete exon-intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction." in: Genomics, Vol. 30, Issue 3, pp. 493-505, (1997) (PubMed).
Meyer, Hatada, Hohmann, Haiker, Bartsch, Röthlisberger, Lahm, Schlaeger, van Loon, Scheidereit: "Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, Issue 3, pp. 966-70, (1991) (PubMed).
Kieran, Blank, Logeat, Vandekerckhove, Lottspeich, Le Bail, Urban, Kourilsky, Baeuerle, Israël: "The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product." in: Cell, Vol. 62, Issue 5, pp. 1007-18, (1990) (PubMed).
Bours, Villalobos, Burd, Kelly, Siebenlist: "Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs." in: Nature, Vol. 348, Issue 6296, pp. 76-80, (1990) (PubMed).
Target
NFKB1
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 1 (NFKB1))
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling, active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.